Enteris BioPharma begins study of its oral drug to treat UTIs

Enteris Biopharma to begin clinical study of oral treatment for UTIs.

Enteris BioPharma, a privately held API company, launched a clinical program for its oral tablet formulation of Tobrate (tobramycin) designed to be used for the treatment of uncomplicated urinary tract infections.

The FDA accepted Enteris’ Investigational New Drug application for Tobrate in April. Under the Phase I study, the drug will be evaluated in a randomized, double-blind, single ascending dose/multiple ascending dose with 24 healthy patients. The data from the study is expected to be complete in early 2017, the company said.

Uncomplicated UTI’s affect about 10 million women in the U.S. each year, according to Enteris. Tobrate will use the company’s Peptelligence platform that allows oral delivery of molecules that are typically injected.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

“We now have the opportunity to advance a potentially high-value and highly differentiated therapeutic for the treatment of uUTI,” Joel Tune, CEO, said in a statement. 

Additionally, the company announced it is partnering with RRD International, a product development company, to develop Tobrate. RRD is expected to provide regulatory and clinical development support for the drug through the end of the Phase II meeting with the FDA. 

Enteris, which was formed in 2013 and is based in New Jersey, got its start after buying the Peptelligence platform, a nasal delivery technology and the recombinant manufacturing process from Unigene Laboratories.

- check out the release

Related Articles:
New Jersey company investing up to $1M in plant, now offers contract manufacturing
Scientists unveil rapid diagnostic for urinary tract infections

Read more on

Suggested Articles

Getting into the program sets Toralgen up to meet with the FDA’s emerging technology team to resolve potential technical and regulatory issues.

The data cover the use of application of DehydraTECH to HIV drugs but Lexaria is also exploring its use in the enhancement of COVID-19 antivirals.

Ad Environment Matters for Message Receptivity